Home / Intelligence / Webinars / The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
Available On Demand
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies?
In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations. However, products with robust clinical differentiation or superiority can achieve price premiums over benchmarks.
Looking ahead, a recent policy to establish a Category C drug list is energizing the pharma industry, potentially providing coverage through government-guided commercial insurance for high-cost, innovative products not included in the NRDL.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will evaluate the impact of the value-rating system on NRDL negotiations, explore successful outcomes across therapeutic areas and introduce potential commercial pathways to inform strategic go-to-market planning for novel therapies.
Key Topics
- Overview of the 2024 China NRDL update: Changes, trends and outcomes
- Case studies across oncology, rare diseases and chronic conditions: Learnings from successful products
- Introduce the Category C and potential commercial access in the future
- Recommendation and outlook for future China pricing and access opportunities
Featuring
Max Hunt
Partner,
Value, Access & Pricing
Wenting Zhang
Director,
Evidence, Value, Access & Pricing
Allen Liu
Senior Consultant & APAC Expert,
Strategic Advisory
Rya Zhang
Consultant,
Value, Access & Pricing
Complete the form below to view the on-demand webinar
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
This webinar will be hosted within the ON24 platform, which requires the usage of Javascript and Cookies. Please see ON24’s Privacy Policy for more information.
Related Intelligence
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More